论文部分内容阅读
目的:观察dl-3-正丁基苯酞(恩必普)软胶囊治疗急性脑梗死的临床疗效和安全性。方法:选择87例首次发作的急性脑梗死患者,治疗组40例、对照组47例。治疗组试验药dl-3-正丁基苯酞软胶囊,每次口服200mg,tid。对照组用药为复方丹参注射液,治疗组加用对照组用药。结果:治疗组与对照组治疗后第11和2l天的神经功能评分和生活能力评定差异有显著性。治疗组治疗前、后实验室数据无显著性差异。结论:dl-3-正丁基苯酞软胶囊治疗急性脑梗死的临床疗效明显,对肝和肾功能、血脂、血糖、EKG无明显影响,不良反应少,临床用药安全。
Objective: To observe the clinical efficacy and safety of dl-3-n-butyl phthalide (enbipu) soft capsule in the treatment of acute cerebral infarction. Methods: A total of 87 patients with acute cerebral infarction who were first attacked were selected, 40 in the treatment group and 47 in the control group. Treatment group test drug dl-3-n-butylphthalide soft capsules, each oral 200mg, tid. Control group for the compound Danshen injection, the treatment group plus the control group medication. Results: There was significant difference in neurological function score and life ability assessment between the treatment group and the control group on the 11th and 21st days after treatment. The treatment group before and after the laboratory data showed no significant difference. Conclusion: The clinical efficacy of dl-3-n-butylphthalide soft capsule in the treatment of acute cerebral infarction is obvious. It has no obvious effect on liver and kidney function, blood lipid, blood glucose, EKG, less adverse reactions and clinical medication safety.